In the present work we investigated the role and biological significance of mitogen activated protein kinases (MAPK) in Bcell chronic lymphocytic leukaemia (B-CLL). The MAPK p38 was constitutively activated in B-CLL, but not in normal peripheral B cells. In addition, we demonstrated that the upstream kinases of p38, MKK3/6 were also constitutively activated in B-CLL cells. Furthermore, we determined by EMSA that the p38 MAP kinase pathway was not linked to the constitutive high expression of NF-jB, a critical survival factor of B-CLL cells. Recently, it has been shown that serum levels of angiogenic factors like VEGF, bFGF and MMP-9 are elevated in the serum of CLL patients and correlate with an unfavorable prognosis. We showed that the constitutive expression of MMP-9 was dependent on p38-activity and inhibition of p38 strongly downregulated MMP-9 expression. Coculture of B-CLL cells and stromal cells can protect spontaneous apoptosis of leukemic B cells. To determine the role of permanently activated p38 and MMP-9 expression, we cocultured B-CLL cells with bone marrow stromal cells. Survival of B-CLL cells on stroma was severely impaired when p38 was inhibited. Furthermore, blockade of MMP-9 activity also antagonized the antiapoptotic effect of stromal cells.
Introduction
Constitutively activated signaling pathways are a hallmark of Bcell chronic lymphocytic (B-CLL) and contribute to the defect of apoptosis. Examples for activated pathways are the constitutive activation of the transcription factor NF-kB 1 as well as constitutive serine phosphorylation of STAT1 and STAT3. 2 We have recently shown that the phosphatidylinositol 3-kinase (PI 3-K) pathway is also constitutively activated in B-CLL cells and is linked to protein kinase C (PKC)-d. 3 Mitogen-activated protein (MAP) kinases are found in all eukaryotes and mediate the effects of numerous extracellular stimuli on a variety of biological processes. 4 So far, three wellcharacterized groups of mammalian MAP kinases have been identified: the extracellular signal-regulated protein kinases (ERK-1/2), 5 the c-Jun N-terminal kinases (JNK1/2/3) 6 and the p38 stress-activated protein kinases (p38SAPK). 7 The p38 MAP kinase include the isoforms p38a/b/g and p38d. 8 MAP kinase cascades contain at least three protein kinases that work in series: MAP kinases (MAPK) are activated by phosphorylation by the action of MAPK kinase (MKK/MEK). The third component of the signaling cascade is the MAPKK kinase. MKKs are highly selective in phosphorylating specific MAPK.
p38 MAPKs are widely expressed in many tissues and are activated by dual phosphorylation on threonine (Thr)-180 and tyrosine (Tyr)-182 residues in a regulatory TXY motif present in all MAPK. 9 The protein kinase MKK-6 has been found to be a very specific upstream regulator of p38 isoforms, 10 but MKK-3 and MKK-4 also contribute to the phosphorylation of certain p38 isoforms. 11 In general, p38 becomes activated by a variety of cellular stress including inflammatory cytokines, lipopolysaccarides (LPS) and osmotic stress. 12 There is increasing evidence that p38 is involved in many other events. For instance, p38 is essential for cytokine gene expression, 13 muscle differentiation 14 and B-cell proliferation. 15 Several transcription factors have been described to be activated by p38. Nuclear targets of p38 are the transcription factor AP-1, 4 CREB, 16 CHOP 17 and ATF-2, which are activated by phosphorylation.
Recent studies have indicated that angiogenesis is increased in B-CLL, according to elevated serum levels of proangiogenic soluble factors like vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Furthermore, it has been reported that B-CLL cells synthesize matrix metalloproteinase-9 (MMP-9), 18 which plays a critical role in tumorangiogenesis and tumor homing. Elevated serum levels of MMP-9 might predict an early disease progression in B-CLL. 19 MMPs are a family of zinc-and calcium-dependent proteolytic enzymes capable of degrading virtually all components of the extracellular matrix (ECM). MMPs are divided into collagenases, stomelysins and gelatinases; the latter group consists of gelatinase A (MMP-2) and gelatinase B (MMP-9), which degrades denatured collagens (gelatine), native type IV and V collagens and elastine and many more such as surface molecules and receptors. By that, MMP-2 and MMP-9 play a critical role in the invasion of bone marrow (BM) by tumor cells. Many growth factors, cytokines, tumor promoters and oncogenes induce MMP-9 protein expression through the activation of its gene promoters by signal transduction pathways. The MMP-9 promoter contains several binding sites for the transcription factor NF-kB 20 and activator protein-1 (AP-1).
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The latter mediates p38-induced upregulation of MMP-9.
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Despite the strong evidence of enhanced MMP-9 serum levels in B-CLL patients and its association with unfavorable prognosis, little is known about the biological significance for the development and maintenance of chronic B-cell leukaemia.
In the present work we report that p38 MAPK is constitutively activated and regulates MMP-9 secretion of B-CLL cells. We further demonstrate that both, p38 MAPK and MMP-9, are important for survival of B-CLL cells on human bone marrow stromal cells.
Materials and methods

Cell samples
After informed consent, peripheral blood was obtained from at least 3-month untreated patients with a diagnosis of B-CLL.
At the time of analysis all patients were clinically stable, free from infectious complications and undergoing routine clinical outpatient review. Control samples were obtained from peripheral blood of healthy donors.
Separation procedures
Peripheral blood mononuclear cells (PBMNC) were isolated from heparinized blood samples by centrifugation over a FicollHypaque layer (Biochrom, Berlin, Germany) of 1.077 g/ml density. For separation of CLL B cells, PBMNC were incubated with anti-CD2 and anti-CD14 magnetic beads (Dynabeads M450, Dynal, Oslo, Norway) according to the manufacturer's instructions. After separation, B cells from CLL patients were 498% pure as assessed by direct immunofluorescence. For separation of peripheral blood B cells of healthy donors PBMNC were incubated with anti-CD19 magnetic beads and isolated B cells were released from CD19 beads by using CD19 DETACHaBEAD s (Dynal biotech, Oslo, Norway). Cells were harvested under ice-cold conditions and were cultured in RPMI 1640 (Biochrom) supplemented with 10% foetal calf serum at 371C and 5% CO 2 in a fully humidified atmosphere.
Reagents and antibodies
Commercial antibodies against p38 MAPK, MKK-3 and phospho-MKK3/6 were produced by cell signaling technology (Frankfurt am Main, Germany), against phospho-p38 MAPK by New England Biolabs (Frankfurt am Main, Germany); antiphospho-c-Jun(Ser63) and anti-p50 NF-kB were obtained from upstate biotechnology (Lake Placid, NY, USA); MAb specific for c-Jun (clone H-79), Erk-1 (clone c-16) and p-Erk (clone E-4) were purchased from Santa Cruz biotechnology (Santa Cruz, USA). The proteinkinase inhibitor SB203580 was obtained from Calbiochem (Schwalbach, Germany) as well as Anti-c-Jun (Ser73) Ab. Blocking antibody against MMP-9 (clone Ab-1) was obtained from Oncogene Research products (San Diego, USA) as well as the negative control antibody for mouse monoclonal IgG 1 (clone trpE).
Immunoblotting
To investigate cell proteins via Western blot 1 to 10 Â 10 7 cells were lysed in lysis buffer (10 mM Tris/HCl (pH 7.4), 5 mM EDTA, 130 mM NaCl, 1% Triton, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na 3 VO 4 and 10 mg/ml of each phenantroline, aprotinin, leupeptin and pepstatin) for 20 min at 41C. Lysates were spun at 12 000 rpm for 20 min and supernatants were collected. Protein concentration was assessed by the Bio-Rad assay method (Bio-Rad Laboratories, Richmond, Canada). Total extracts (40 mg/lane) were subjected to SDS-PAGE and blotting was performed on PVDF membranes (Immobilon-P, Millipore GmbH, Germany).
p38 kinase assay
Nonradioactive p38 kinase assay kit was purchased from New England Biolab. After immunoprecipitation of p38 MAPK, the kinase reaction was performed according to the manufacturer's instructions using ATF-2 protein as an exogenous substrate. The kinase reaction was analyzed by immunoblotting, using a phospho-ATF-2 antibody.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared and analyzed as described elsewhere. 23 The binding of NF-kB was determined by EMSA using specific consensus oligonucleotides (Promega, Heidelberg, Germany) labelled with 20 mCi (0.37 MBq) [g- 32 P]ATP and T4 polynucleotide kinase (Boehringer Mannheim). Nuclear extracts (5 mg of protein) were incubated with radiolabelled DNA probes (B10 ng) for 30 min at room temperature in 20 ml of binding buffer (20 mM HEPES, pH 7.9, 59 mM KCl, 1 mM dithiothreitol, 0.5 mM EDTA, 10% glycerol, 1 mg/ml bovine serum albumin, 0.2% Nonidet P-40, 50 ng of poly(dI-dC)/ml). Samples were run in 0.25 Â TBE buffer (10 Â TBE is as follows: 890 mM Tris, 890 mM boric acid, 20 mM EDTA, pH 8.0) on nondenaturing 4% polyacrylamide gels. Gels were dried and analyzed by autoradiography. Supershifts were performed by the addition of 2 mg mAb against p50-NF-kB to the nuclear extracts.
Analysis of apoptosis
Cells were washed with PBS and resuspended in 500 ml binding buffer (Annexin V-FITC Kit, Immunotech) containing 1 ml of Annexin V-FITC stock and 5 ml of 20 mg/ml PI to determinate the PS exposure on the outer plasma membrane. After incubation for 10 min at room temperature, the specimens were quantified by flow cytometry, acquiring 5000 events.
Cytokine measurements
Cytokine levels were determined after a 72-h culture period of 2 Â 10 6 cells/ml with the use of commercially available enzymelinked immunosorbet assay kits (R&D systems, Wiesbaden, Germany).
Measurement of MMP-9 activity by zymography
For zymograms 10 ml 4 Â nonreducing loading buffer (50% Glycerol, 160 mM Tris-HCl (pH 7.5), 8% SDS, 0.08% Bromphenol blue) was added to 30 ml cleared culture supernatant and separated by 8% SDS-PAGE containing 0.6 mg/ml gelatine (Calbiochem). The gel was washed twice with wash buffer (50 mM Tris-Hcl (pH 7.5), 150 mM NaCl, 5 mM CaCl 2 , 0.05% NaN 3 , 2.5% Triton X-100) for 30 min to remove the SDS followed by a 20-h incubation in the same buffer (without Triton X-100) at 371C with gentle agitation. MMP-9 activity was visualized by staining the gel with 0.2% Coomassie blue.
In vitro survival assay of CLL cells on allogenic bone marrow stromal cells
In total, 5 Â 10 6 purified B-CLL cells were seeded onto the stroma cell monolayer in RPMI-1640 supplemented with 10% FCS and penicillin-streptomycin-glutamine. B-CLL cells were untreated or preincubated for 1 h with SB203580 at 371C. Before coculture with stromal cells, the inhibitor was removed by washing cells twice in medium alone. A blocking antibody against MMP-9 (10 mg/ml) was added to the medium as indicated. After incubation for 72 h, viable cells were removed from the culture by vigorously washing the wells with RPMI medium three times. Cells were stained with trypan-blue and viable cells were counted in a Neubauer-chamber or FACS analysis. In separate experiments, all cells were removed from the well using 1 ml prewarmed trypsin/EDTA solution. Then, cells were immediately suspended in 5 ml RPMI/10% FCS and wells were washed again with medium alone. The entire cell solution was analyzed by flow cytometry. B-CLL cells were stained with a PE-labelled anti-CD19 Ab. Then 50 000 beads (Flow-countt fluorospheres, Beckman Coulter, Krefeld, Germany) were added to each sample. Beads were counted and measuring was stopped at 5000 beads. The relationship between beats and counted CD19-positive cells revealed the absolute cell number of leukemic cells per well.
Statistical analysis
Data from individual experiments are presented as mean7 s.e.m. Statistical significances were determined using the Wilcoxon signed rank test and the Mann-Whitney test as appropriate. A P-value o0.05 was considered to be statistically significant.
Results
Constitutive activation of p38SAPK in B-CLL cells
We first examined the activation of different MAPKs in freshly isolated B-CLL cells. p38 was phosphorylated in six out of six different CLL-samples (Figure 1a) . In contrast to leukemic B cells, peripheral B cells of healthy donors did not contain phosphorylated forms of p38. Interestingly, phosphorylation was present in all tested samples, regardless of Binet stage, ZAP-70 expression or number of previous therapies (data not shown). Next, we investigated whether Erks were activated in freshly isolated B-CLL cells. The representative analysis in Figure 1b shows that Erk was not activated in leukemic B cells. Furthermore, we failed to detect constitutively activated c-Jun in B-CLL cells. The level of protein expression of c-Jun was quite low (Figure 1c ). These data demonstrate that MAPK are expressed in B-CLL cells, but only the p38SAPK is constitutively activated, whereas Erk-and c-Jun activation cannot be detected in B-CLL samples.
We confirmed in a p38 MAP in vitro-kinase assay that phosphorylation of the protein correlates with kinase activation. Kinase activity was detected by phosphorylation of the p38 substrate ATF-2. Surprisingly, activation of p38 MAPK remained stable over 24 h during in vitro culture in medium supplemented with 10% FCS (data not shown). Due to variations regarding the concentration of the pyridinyl imidazole inhibitor SB203580 required to block p38 activity, we tested two concentrations (1 and 5 mM) of SB in this p38 kinase assay. As there was no evidence of inhibition of p38 kinase activity at 1 mM in this assay, we have chosen a working concentration of 5 mM for further tests (Figure 2a) .
We considered that the differences in phosphorylation between normal peripheral B cells and leukemic B cells might have been due to different separation and purification protocols. Therefore, B-CLL cells were either negatively or positively purified. CD19 ligation of B-CLL cells did not change the level of p38 MAPK phosphorylation compared to negatively selected samples (Figure 2b ).
The upstream kinases MKK-3 and -6 are also constitutively activated in B-CLL cells
The MAP kinase kinases MKK3 and MMK6 activate p38 by dual phosphorylation. The activation of MKK3 and MKK6 is regulated by phosphorylation on critical serine and threonine residues by MAP kinase kinase kinase (MKKK). 11 We analyzed the involvement of MKK3 and MKK6 in the constitutive activation of p38 MAPK in B-CLL cells. As shown in Figure 3 , MKK3 and MKK6 were constitutively activated in B-CLL cells, in contrast to B cells of normal donors. We conclude from this data that p38 MAPK is constitutively activated through a pathway that involves MKK3/6.
Inhibition of p38 MAPK does not induce apoptosis nor effect NF-kB activation were treated with the p38 MAPK inhibitor SB203580 for 24 h. It is worthwhile to mention that SB203580 is stable over 24 h during in vitro culture. 24 The number of apoptotic cells was determined by Annexin-V/ PI staining and compared to spontaneous apoptosis in vitro. As demonstrated in Figure 4a , inhibition of p38 MAPK did not induce apoptosis in this assay.
Schattner and co-workers 1 have demonstrated that the profound defect of apoptosis in B-CLL is linked to high levels of constitutively activated NF-kB. In order to specify whether p38 MAPK is linked to NF-kB in B-CLL cells, cells were incubated with SB203580 and nuclear extracts were prepared after the indicated time. NF-kB activity was evaluated by using electrophoretic mobility shift assays (EMSA). Inhibition of the p38 MAPK did not affect binding of NF-kB to DNA in B-CLL cells (Figure 4b) . Specification of the binding was tested either by the addition of an unlabeled probe (competition) or by using an antibody specific for p50. These data indicate that the enhanced constitutive activation of NF-kB in B-CLL cells is independent of p38 MAPK.
p38 regulates secretion of MMP-9 in B-CLL cells, but not of VEGF or bFGF
As p38 MAPK regulates the expression of many cytokines in context with inflammatory responses, 13 we analyzed whether the constitutively activated p38 MAPK was involved in the secretion of soluble factors by B-CLL cells. Cells were incubated in medium with or without the p38 kinase inhibitor SB203580 for 72 h and supernatants were analyzed by ELISA. Owing to the recent report that B-CLL cells synthesize angiogenetic factors like bFGF, VEGF and MMP-9, 18 we analyzed the contribution of p38 MAPK activity on the secretion of these soluble factors. The basal expression of VEGF and bFGF did not change due to the inhibition of p38 MAPK during in vitro culture of B-CLL cells (Figure 5b and c) . In contrast, we observed Inhibition of p38 MAPK does not induces apoptosis or effect NF-kB binding to DNA: B-CLL cells were incubated over the time period of 24 h with SB203580 (5 mM). (a) The number of apoptotic cells was determined by Annexin-V/PI staining. (b) NF-kB binding was measured by electromobility shift assay (EMSA) using specific, 32 P-g-ATP-labeled consensus oligonucleotides. Immediately after separation (T 0 ) or at the indicated time points nuclear proteins were extracted. A total of 5 mg of protein from each nuclear extract was used. Arrows indicate specific NF-kB bands. Specificity was confirmed either by the addition of a cold, unlabelled consensus oligonucleotide (lane 2) or by supershift EMSA using an antibody to the p50-subunit of NF-kB (lane 9). One representative experiment out of three is shown. Lanes were loaded equally as determined by an EMSA using an oligonucleotide specific for SP-1 (data not shown).
p38 mediates survival of B-CLL cells on stromal cells I Ringshausen et al a strong downregulation of MMP-9 secretion by blocking p38 MAPK function (45327812 vs 6027228 pg/ml; P ¼ 0.0178) (Figure 5a ). As MMP-9 is secreted as an inactive proenzyme and becomes activated after proteolytic cleavage of the molecule, we tested its activity by gelatine zymography. Figure 5d shows that MMP-9 was biologically active and that p38 MAPK inhibition severely suppressed MMP-9 secretion and activation in vitro.
The p38 MAPK and MMP-9 are important for survival of B-CLL cells on bone marrow stromal cells
Despite the long half-life of B-CLL cells in vivo, cells rapidly die during short-term culture in vitro. Lagneaux and co-workers 25 have reported that leukemic B cells can be rescued from apoptosis by contact with bone marrow stromal cells. These findings prompted us to evaluate the significance of constitutively activated p38 MAPK and secreted MMP-9 for the survival of B-CLL cells on stromal cells. In total, 5 Â 10 6 B-CLL cells were cultured on BM stromal cell monolayer for 72 h. B-CLL cells were preincubated for 60 min with SB203580 at 371C and then the inhibitor was removed by washing cells twice in medium alone. MMP-9 activity was antagonized by adding a neutralizing antibody against MMP-9 to the culture. The assay was analyzed by counting the number of viable B-CLL cells either by trypanblue staining/light microscopy or by FACS analysis. Surprisingly, blocking p38 MAPK activity severely diminished the number of viable cells (56.776.2%; P ¼ 0.0005; Figure 6a ) detectable after 3 days compared with untreated control samples (100%). Significant impairment of survival of B-CLL cells on stromal cells also was observed when MMP-9 activity was blocked by the addition of an anti-MMP-9 mAb to the culture (63.474.3%; P ¼ 0.0001; Figure 6a ). The MMP-9 mAb had no effect on the survival of B-CLL cells cultured in the absence of stromal cells (data not shown). A nonspecific Ab did not affect the number of viable cells compared to the medium control (10074.3%; P ¼ 0.948). We conclude that both p38 MAPK and MMP-9 seem to be important for the survival of B-CLL cells on BM stromal cells.
In order to determine how long after exposure to SB203580 p38 kinase activity is inhibited, we conducted a p38 in-vitro kinase assay analogous to the previous experiment. B-CLL cells were incubated for 1 h with 5 mM SB203580 before cells were washed and cultured only in medium supplemented with FCS. After various time points, p38 kinase was isolated by immunoprecipitation and the kinase activity was analyzed by an in vitro kinase assay. Surprisingly, inhibition of p38 MAPK by SB203580 resulted in a long-lasting decrease of p38 kinase activity as shown in Figure 6b . As SB203580 is a reversible inhibitor of p38 MAPK that inhibits p38 kinase in a manner competitive with ATP, SB203580 is washed out during the purification of the immunopecipitated complex of p38 from whole-protein lysates. Therefore, the decrease of p38 kinase activity is unlikely to be a direct effect of SB203580. The underlying mechanism is not clear at the moment but we are currently investigating this interesting new finding. These data support the importance of 
Discussion
Our investigations provide evidence that p38 MAPkinase is constitutively activated in B-CLL cells, whereas resting normal peripheral B cells harbor nonactivated p38 MAPK. Over the last couple of years, the general function of MAPK has been divided into promitogen effects mediated by Erk, in contrast to p38 and c-Jun SAPK, which are rather thought to promote cell death. 26 An increasing number of data has pointed out that this dichotomy does not completely hold true. Indeed, in B-CLL, p38 MAPK seems to be involved in the induction of apoptosis either induced by the vitamin D 3 analog EB1089 27 or by the monoclonal antibody rituximab. 28 Pepper et al have reported that the induction of apoptosis by EB1089 is mediated through p38, but chlorambucil-induced apoptosis is not p38 dependent. 27 Pedersen et al 28 have demonstrated dependence on p38 MAPK for the induction of CD20-mediated apoptosis, but complete inhibition of p38 activity resulted only in a partial inhibition of apoptosis. Both drugs certainly do not induce apoptosis only by activation of p38 MAPK, but apoptosis induced by rituximab or EB1089 may be accompanied by activation of p38. Therefore, p38 does not seem to be necessarily linked to apoptosis in B-CLL and we do not believe that those data are in conflict with our results. However, p38 MAPK is also involved in antiapoptotic events and contributes to the pathogenesis of lymphoproliferative disorders. For instance, there is evidence that p38 MAPK indirectly promotes the growth of multiple myeloma cells in response to growth factors. 29 Furthermore, p38 MAPK is activated in diffuse large B-cell lymphomas and lymphoma growth in NOD-SCID mice is inhibited by the treatment of mice with SB203580. 30 In accordance with data linking p38 MAPK to lymphomagenesis and not only to apoptosis, we did not observe induction of apoptosis when B-CLL cells were cultured with the p38 MAPK inhibitor SB203580 in the absence of stromal cells. Therefore, it seems unlikely that constitutively activated p38 MAPK plays a proapoptotic role just by itself in these cells.
One important question that arises from our work is what activates p38 MAPK in B-CLL cells? Under physiological conditions, MAPK are generally activated in response to an exogenous stimulus, for example cytokine receptor ligation. This might also be the case for B-CLL cells, but the matter of fact that p38 MAPK maintained phosphorylated over 24 h during in vitro culture rather requires different pathomechanism(s): (I) A cell 'extrinsic' mechanism that causes a permanent interaction between a cell surface-receptor and ligand: Schattner et al have proposed that the interaction between CD40 and CD154, which are both expressed on a subset of malignant B cells, can contribute to a stage of activation and activate NF-kB in particular. The interaction between BCR, which often binds autologous structures, 31 and host antigens has also to be considered to permanently activate B-CLL cells. Certainly, this does not explain the long-lasting activation of p38 MAPK during in vitro culture. (II) p38 MAPK could be activated due to a cell 'intrinsic' defect either by a deregulated upstream oncogene or by a disturbed mechanism of deactivation by phosphatases. Our present work demonstrates that constitutively activated p38 MAPK regulates the expression and secretion of MMP-9 by B-CLL cells and is important for the transmission of antiapoptotic signals provided by stromal cells. We are aware that the simplicity implicated by this single pathway does not represent the complexity of the interaction between malignant B cell and stromal cell. Most likely, the impaired survival of B-CLL cells lacking functional p38 MAPK on human bone marrow stromal cells is not only a consequence of decreased MMP-9 secretion. MMP-9 may contribute to antiapoptotic effects mediated by stromal cells, either by the release of soluble, matrix-bound proteins and/or by the modulation of surface molecules. For instance, MMPs can cleave the cell-membrane bound precursor form of TNFa to generate active, soluble TNFa. 32 TNFa itself is produced by B-CLL cells and contributes to cell survival in an autocrine manner. 33 Moreover, it has been reported by Bauvois et al 18 that TNFa upregulates MMP-9 secretion of B-CLL cells, suggesting a positive feed back mechanism. We investigated supernatants from CLL/stroma cocultures either untreated or treated with a blocking mAb against MMP-9 or SB203580 by ELISA. The level of TNFa expression remained unaffected by inhibition of MMP-9 or p38 MAPK (data not shown). Therefore, impaired survival of B-CLL cells lacking functional p38 MAPK or MMP-9 activity does not seem to be based on decreased TNFa levels in CLL/stroma cocultures. MMP-9 may also remodel the ECM, which can result in the release of otherwise sequestered structures. Such an interaction has been shown to promote survival and growth of melanoma cells. 34 There is no doubt that the microenvironment supports B-CLL cell survival in vivo, as cells die rapidly in vitro during short-term culture in media supplemented by fetal bovine serum. 35 A number of previous studies have shown that BM stromal cells 25 or follicular dentritic cells 36 can rescue malignant B cells from spontaneous apoptosis. This antiapoptotic effect is dependent on a direct contact between leukemic cells and stromal cells as stromaconditioned medium failed to rescue B-CLL cells from apoptosis. Adhesion is partly mediated by b 1 -and b 2 -integrins, CD106 and CD54. Burger et al 37 recently published that migration of leukemic B cells beneath bone marrow stroma cells (pseudoemperipolesis) requires stromal cell-derived factor-1 (SDF-1). In human endothelial cells, thrombin induces the expression of CD54 via activation of PKC-d/p38 MAPK. 38 Therefore, we investigated the expression of CD54 on B-CLL cells with or without the p38 inhibitor. Although SB203580 did not affect the level of expression of surface ICAM-1 on B-CLL cells (data not shown), p38 MAPK might be important for cell adhesion on stromal cells and further experiments to address this issue are needed.
It has been demonstrated in solid tumors that targeting the interaction between malignant cells and surrounding stromal cells has an antitumoral capacity. 39, 40 This may also be true for haematological tumors and combined therapies, targeting apoptotic checkpoints, signaling pathways and the microenvironment can offer promising new treatment strategies. Our studies identify the p38 MAPK-pathway as a novel therapeutic target to improve the treatment of B-CLL patients.
